Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7509211 | Drug and Alcohol Dependence | 2011 | 5 Pages |
Abstract
These results highlight the difficulties in alcohol consumption assessment which HCV specialists may face when suggesting to their HIV/HCV co-infected patients that they cease drinking completely. Patient awareness about the real need to reduce their alcohol use before starting HCV therapy may also contribute to underreporting. Innovative strategies for alcohol risk-reduction, including the promotion of controlled consumption and access to multidisciplinary teams, should be implemented for HIV/HCV co-infected patients in order to reduce barriers to HCV treatment.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
P. Roux, J. Cohen, C. Lascoux-Combe, P. Sogni, M. Winnock, D. Salmon-Ceron, B. Spire, F. Dabis, M.P. Carrieri, for the ANRS-CO13-HEPAVIH Study Group for the ANRS-CO13-HEPAVIH Study Group,